Formulation, Evaluation and Optimization of Orodispersible Tablets of Naproxen Sodium 250 Mg

  • Mohd. Razi Ansari
  • Sumer Singh
  • Majaz Quazi
  • YAASIR AHMED ANSARI
  • Abbas Jameel

Abstract

Among the different type of route of administration oral route for drug administration is most common route in which Orodispersible tablet is preferred for the patient which are unconscious, week or for immediate control. The tablet gets dispersed in mouth cavity without water, present study deals with formulation of Naproxen sodium mouth dissolving tablets using super disintegrants. Naproxen sodium is analgesic and NSAID, used for the treatment of pain and inflammation caused by different condition such as osteoarthritis, rheumatoid arthritis and menstrual cramps. However gastric discomfort caused by naproxen sodium result in poor patient compliance associated with it conventional doses form but now days Naproxen sodium MDTs produces rapid onset of action and minimise gastric discomfort associated with it. Thus improves patient compliance, enhance bioavailability and reduces the dose of drug. MDTs are formulated by direct compression method using super disintegrants in different proportion. The powder blend is subjected to pre-compression evaluation parameters like bulk density, true density, and tapped density and angle of repose. Formulations are evaluated for weight variation, hardness, wetting time, water absorption time, disintegration time. And in vitro dissolution studies and all formulations complies Pharmacopoeias standards. The tablets are evaluated and result compared for all five formulation the most efficacious super disintegrants for MTDs of Naproxen sodium as suggested by the dispersion time, disintegration time and drug dissolution profiles.

Downloads

Download data is not yet available.
Statistics
18 Views | 64 Downloads
How to Cite
Ansari, M. R., Singh, S., Quazi, M., ANSARI, Y. A., & Jameel, A. (2019). Formulation, Evaluation and Optimization of Orodispersible Tablets of Naproxen Sodium 250 Mg. Journal of Drug Delivery and Therapeutics, 9(4), 544-549. https://doi.org/10.22270/jddt.v9i4.3197